Medical Crossfire®: Residual Inflammatory Risk In Atherosclerosis: Clinical Pearls For Clinicians

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

On-demand Medical Crossfire® activity

Faculty Speakers

Christie M. Ballantyne, MD
Professor of Medicine, Department of Medicine
Chief, Section of Cardiology
Chief, Section of Cardiovascular Research
Baylor College of Medicine
Director, Center for Cardiovascular Disease Prevention
DeBakey Heart and Vascular Center
Houston Methodist Hospital
Houston, Texas
Peter Libby, MD
Brigham and Women’s Hospital
Cardiovascular Medicine
Harvard Medical School
Boston, Massachusetts
Paul M. Ridker, MD
Eugene Braunwald of Professor of Medicine
Harvard Medical School
Director, Center for Cardiovascular Disease Prevention
Brigham and Women’s Hospital
Boston, Massachusetts
Robert S. Rosenson, MD
Director, Cardiometabolics Unit
Mount Sinai Hospital
Professor of Medicine (Cardiology)
Icahn School of Medicine at Mount Sinai
New York, New York

Activity Overview

Atherosclerosis, formerly considered a bland lipid storage disease, actually involves an ongoing inflammatory response. Recent advances in basic science have established a fundamental role for inflammation in mediating all stages of this disease from initiation through progression and, ultimately, the thrombotic complications of atherosclerosis. These new insights into inflammation in atherosclerosis not only increase our understanding of this disease, but also have practical clinical applications in risk stratification and targeting of therapy for this scourge of growing worldwide importance.
During this Medical Crossfire, expert faculty will engage in a roundtable discussion on these topics and present brief overviews on the pathogenesis of inflammation in atherosclerosis, the use of inflammatory biomarkers in patient assessment for secondary CVD risks, and evidence demonstrating the pleiotropic effects of statins and benefits and risks of current and novel agents for the treatment of inflammation in the prevention of secondary CVD risks. The goal is to bring more attention to the role of inflammation in the initiation and progression of atherosclerosis and as a treatment target for patients at risk.

Educational Objectives

At the completion of this activity, the participant will be able to:
  • Articulate the role of inflammation in the pathogenesis of atherosclerosis
  • Describe best practices for incorporating inflammatory biomarkers into cardiovascular risk assessment procedures to prevent secondary CVD risk
  • List the pleiotropic effects of statins, specifically their anti-inflammatory properties
  • Summarize recent data on emerging agents that target inflammation for secondary prevention of CVD in order to provide optimal outcomes for patients at risk

Become a Member

Forgot Password?
Calendar of Events
Filter By